Close
Achema middle east
swop processing & packaging

Drug Research

NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development

NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and...

Idorsia forms research collaboration with Roche in the field of cancer immunotherapy

Idorsia Ltd announced that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds...

NorthSea Therapeutics Secures €25 Million Funding for Clinical Development of Promising NASH Drug

NorthSea Therapeutics B.V. , a newly established Dutch biotech company, announced the completion of a €25m Series A funding for the development of icosabutate, a...

Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® Breast Cancer Kit Co-Validation Study

Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer....

Torque Launches Platform to Develop New Class of Deep Primed Immune Cell Therapies

Torque, an immuno-oncology company developing Deep Primed cell therapies that direct and evoke immune responses in the tumor microenvironment, announced the launch of its technology...

Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December

Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on...

ANTABIO Raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-Negative Infections

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »